Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ion of the purchase price to the assets acquired and liabilities assumed, based on their fair values.

Book Value Fair Value Fair Value

Adjustments

US$M US$M US$M

____________ ___________ ___________

Non-current assets:

Other intangible assets, net

- Intellectual property -

developed technology - 1,133.3 1,133.3

- Favourable manufacturing

contracts - 9.2 9.2

- In process research and

development - 1,943.3 1,943.3

Property, plant and equipment, net 2.6 (1.8) 0.8

Deferred tax assets, non-current 1.1 52.4 53.5

Current assets:

Inventories 4.8 6.6 11.4

Accounts receivable, net 0.3 - 0.3

Prepaid expenses and other

current assets 2.4 (2.2) 0.2

Purchased call option 141.8 - 141.8

Short-term investments 55.8 - 55.8

Cash and cash equivalents 74.9 - 74.9

Non-current liabilities:

Sold warrants (133.0) 133.0 -

Deferred income, non-current (59.5) 59.5 -

Deferred tax liability,

non-current (1.1) (1,109.5) (1,110.6)

Current liabilities:

Convertible loan notes (279.4) - (279.4)

Accounts payable and accrued

expenses (33.3) 1.6 (31.7)<
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 21, 2015 Research ... addition of the "Analysis of the Global ... offering. Globally, flow cytometry remains a ... proliferation, cancer, and stem cells. But the market ... because of demand from underdeveloped nations to quantitate ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... July 28, 2015  Moerae Matrix Inc. announced ... clinical trial with MMI-0100, a first-in-class inhibitor of ... for pulmonary disorders characterized by inflammation and fibrosis.  ... Kingdom , is a double-blind, two-way cross-over ... safety and tolerability of MMI-0100 when given via ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3
... Conn. Two major steps toward putting quantum computers into ... a qubit onto wires and transmitting the signal to a ... team of scientists at Yale. The accomplishments are reported in ... on which it is highlighted as the cover along with ...
... (Nasdaq: PRXL ), a leading global ... of the acquisition,of Taiwan-based APEX International Clinical ... release. In conjunction with the acquisition and ... its forward-looking,financial guidance for the first quarter ...
... 26 Today at the Clinton Global,Initiative ... a,ground-breaking vaccine to eliminate epidemic meningitis in ... developed by the Meningitis,Vaccine Project, a partnership ... produced by Serum Institute of India Limited ...
Cached Biology Technology:Yale scientists make 2 giant steps in advancement of quantum computing 2Yale scientists make 2 giant steps in advancement of quantum computing 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 4PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... The US military wants to buy large quantities of anthrax, ... over its commitment to treaties designed to limit the spread ... uncovered that relate to the US army' Dugway Proving ... production of bulk quantities of a non-virulent strain of anthrax, ...
... dominated this week by the continuing debate over HIV/AIDS ... drugs were not the only way to fight HIV/AIDS, ... previously denying links between HIV and AIDS, the South ... year. As many as five million South Africans are ...
... comes to the deadly skin cancer melanoma, studying ... provide insight into the disease's development, according to ... predoctoral fellow at Stanford University School of Medicine. ... melanoma development, scientists have not been able to ...
Cached Biology News:US Army plans to bulk-buy anthrax 2Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance 2Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance 3
... DNA and RNA endonucleolytically to yield ... DNA:RNA or RNA:RNA) are resistant to ... of enzyme (1). The enzyme is ... double-stranded DNA (2), for selective cleavage ...
Miniature FRENCH Pressure Cell with 3.7ml capacity; pressure up to 20,000 psi....
... Labsystems Nepheloskan Ascent is the ... measurement in microplates. Nepheloskan measures ... ultra-sensitive technique for particle quantification. ... solubility testing in drug discovery, ...
... High Vacuum pumps deliver critical performance for ... ballast control optimizes pump performance to suit ... allows for convenient checking of proper oil ... of pumps is designed to work with ...
Biology Products: